Atypical antipsychotics in the treatment of bipolar disorder

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 751-760

  Strakowski, Stephen M ^a   Del Bello, Melissa P ^a   Adler, Caleb M ^a   Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Aripiprazole; Atypical antipsychotics; Bipolar disorder; Olanzapine; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ADRENERGIC RECEPTOR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LAMOTRIGINE; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; NORADRENALIN; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 2 ANTAGONIST; THIORIDAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

AKATHISIA; AMENORRHEA; ASTHENIA; BIPOLAR DISORDER; BODY WEIGHT DISORDER; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG UTILIZATION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; METABOLIC DISORDER; MUSCLE HYPERTONIA; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; RECEPTOR AFFINITY; RELAPSE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SOMNOLENCE; SPERMATOZOON MOTILITY; TARDIVE DYSKINESIA; VERTIGO; XEROSTOMIA;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; EXPERT TESTIMONY; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0038473860     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.751     Document Type: Review

References (57)

1. GOODWIN FK, JAMISON KR: Manic-depressive illness. Oxford University Press, London, UK (1990).
2. MURRAY CJL, LOPEZ AD: The global burden of disease: summary. Harvard School of public health monograph, Cambridge, MA, USA (1996).
3. PRIEN RF, CAFFEY EM Jr, KLETT CJ: Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch. Gen. Psychiatry (1972) 26(2):146-153.
4. JOHNSON G, GERSHON S, BURDOCK EI, FLOYD A. HEKIMIAN L: Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br. J. Psychiatry (1971) 119(550):267-276.
5. STRAKOWSKI SM, DELBELLO MP, ADLER CM: Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs (2002) 15(9):701-708.
6. MCELROY SL, KECK PE JR., STRAKOWSKI SM: Mania, psychosis and antipsychotics. J. Clin. Psychiatry (1996) 57(Suppl. 3):14-26.
7. AHLFORS UG, BAASTRUP PC, DENCKER SJ et al.: Flupenthixol decanoate in recurrent manic-depressive illness. A comparison with lithium. Acta Psychiatr. Scand. (1981) 64(3):226-237.
8. KECK PE Jr, MCELROY SL, STRAKOWSKI SM: Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry (1998) 59(Suppl. 6):74-81.
9. STRAKOWSKI SM, MCELROY SL, KECK PE Jr: Efficacy of valproate in bipolar illness: comparisons and contrasts with lithium. In: Pharmacotherapy for mood, anxiety and cognitive disorders. Montgomery S, Halbreich U (Eds), American Psychiatric Press Inc., Washington, DC, USA (2000):143-158.
10. TOHEN M, SANGER TM, TOLLEFSON GD et al.: Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry (1999) 156(5):702-709.
11. TOHEN M, JACOBS TG, GRUNDY SL et al.: Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry (2000) 57(9):841-849.
12. SANGER TM, TOHEN M, VIETA E et al.: Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J. Affect. Disord. (2003) 73(1-2):155-161.
13. TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159 (6):1011-1017.
14. ZAJECKA JM, WEISLER R, SACHS G et al.: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63(12):1148-1155.
15. TOHEN M, CHENGAPPA KN, SUPPES T et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry (2002) 59(1):62-69.
16. TOLLEFSON GD, SANGER TM, BEASLEY CM, TRAN PV: A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry (1998) 43(11):803-810.
17. SHELTON RC, TOLLEFSON GD, TOHEN M et al.: A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry (2001) 158(1):131-134.
18. TOHEN M, VIETA E, KETTER TA et al.: Olanzapine in the treatment of bipolar depression. Int. J. Neuorpsychopharmacol. (2002) 5(Suppl. 1):S109
19. TOHEN M, MARNEROS A, BOWDEN C et al.: Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomised double-blind controlled 12-month clinical trial. 41st Annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8 - 12 (2002).
20. NASRALLAH H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology (2003) 28:83-96.
21. ALLISON DB, MENTORE JL, HEO M et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:1686-1696.
22. NEMEROFF CB: Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry (1997) 58(Suppl. 10):45-49.
23. BEASLEY CM: Safety of olanzapine. J. Clin. Psychiatry Monograph (1997) 15:19-21.
24. WEIDEN P, AQUILA R, STANDARD J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry (1996) 57(Suppl. 11):53-60.
25. WIRSHING DA, SPELLBERG BJ, ERHART SM, MARDER. SR, WIRSHING WC: Novel antipsychotics and new-onset diabetes. Biol. Psychiatry (1998) 44:778-783.
26. KORO CE, FEDDER DO, L'ITALIEN GJ et al.: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidaemia in schizophrenic patients. Arch. Gen. Psychiatry (2002) 59:1021-1026.
27. GIANFRANCESCO FD, GROGG AL, MAHMOUD RA, WANG R, NASRALLAH HA: Differential effects of risperidone, olanzapine, dozapine, and conventional antipsychotics on type-2 diabetes: findings from a large health plan database. J. Clin. Psychiatry (2002) 63:920-930.
28. TOHEN M, ZARATE CA Jr, CENTORRINO F, HEGARTY JI, FROESCHL M, ZARATE SB: Risperidone in the treatment of mania. J. Clin. Psychiatry (1996) 57(6):249-253.
29. VIETA E, HERRAIZ M, PARRAMON G, GOIKOLEA JM, FERNANDEZ A, BENABARRE A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J. Affect. Disorder (2002) 72(1):15-19.
30. MCINTYRE R, YOUNG LT, HASEY G, PATELIS-SIOTIS I, JONES BD: Risperidone treatment of bipolar disorder. Can. J. Psychiatry (1997) 42(1):88-90.
31. LICTH RW, BYSTED M, CHRISTENSEN H: Fixed-dosed risperidone in mania: an open experimental trial. Int. Clin. Psychopharmacol. (2001) 16(2):103-110.
32. SACHS GS, GROSSMAN F, GHAEMI SN, OKAMOTO A, BOWDEN CL: Combination of a mood stabiliser with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry (2002) 159(7):1146-1154.
33. HIRSCHFELD R, KECK PE, KARCHER K, KRAMER M, GROSSMAN F: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8 - 12, 2002.
34. MYERS JE, THASE ME: Risperidone: review of its therapeutic utility in depression. Psychopharmacol. Bull. (2001) 35(4):109-129.
35. SHELTON RC, ADDINGTON S, AUGENSTEIN E, BALL W: Risperidone and paroxetine in bipolar disorder. Annual Meeting of the American Psychiatric Association, New Orleans, Louisiana, USA May 5 - 10 (2001).
36. HALBREICH U, KINON BJ, GILMORE JA, KAHN LS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology (2003) 28:53-67.
37. 2A receptor blockade by quetiapine an R91150 single photon emission tomography study. Psychopharmacology (Berl.) (2001) 157:60-66.
38. DEV V, RANIWALLA J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety (2000) 23:295-307.
39. 2 receptor occupancy. Arch. Gen. Psychiatry (2000) 57:553-559.
40. ADITYANJEE, SCHULZ SC: Clinical use of quetiapine in disease states other than schizophrenia. J. Clin. Psychiatry. (2002) 63(Suppl. 13):32-38.
41. FINDLING RL: Use of quetiapine in children and adolescents. J. Clin. Psychiatry (2002) 63(Suppl. 13):27-31.
42. DELBELLO MP, SCHWIERS ML, ROSENBERG HL, STRAKOWSKI SM: A double-blind, randomised, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J. Am. Acad. Child. Adolesc. Psychiatry (2002) 41:1216-1223.
43. SACHS G, MULLEN J, DEVINE N, SWEITZER DE: Quetiapine versus placebo as an adjunct to mood stabiliser for the treatment of acute bipolar mania. Presented at the 3rd European Stanley foundation Conference on Bipolar Disorder, September 12 - 14, 2002.
44. NEMEROFF CB, KINKEAD B, GOLDSTEIN J: Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry (2002) 63(Suppl. 13):5-11.
45. KECK PE Jr, MCELROY SL, ARNOLD LM: Ziprasidone: a new atypical antipsychotic. Exp. Opin. Pharmacother. (2001) 2:1033-1042.
46. KECK PE Jr, REEVES KR, HARRIGAN EP et al.: Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled trials. J. Clin. Psychopharmacol. (2001) 21: 27-35.
47. KECK PE Jr, VERSIANI M, POTKIN S et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomised trial. Am. J. Psychiatry (2003) (In Press).
48. KECK PE Jr, BUFFENSTEIN A, FERGUSON J et al.: Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (1998) 140:173-184.
49. DANIEL DG, ZIMBROFF DL, POTKIN SG et al.: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo controlled trial. Neuropsychopharmacology (1999) 20: 491-505.
50. REILLY JG, AYIS AS, FERRIER IN, JONES SJ, THOMAS SH: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet (2000) 355:1048-1052.
51. KECK PE Jr, MARCUS R. TOURKODIMITRIS S, ALI M, SAHA A, INGENITO G: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry (2003) (In press).
52. MULLER-OERLINGHAUSEN B, RETZOW A, HENN FA et al.: Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomised, double-blind, placebo-controlled multicenter study. J. Clin. Psychopharmacol. (2000) 20:195-203.
53. YATHAM LN, GROSSMAN F, AUGUSTYNS I, VIETA E, RAVINDRAN A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: International, double-blind, randomised controlled trial. Br. J. Psychiatry (2003) 182:141-147.
54. VIETA E, KHANNA S, VAN KAMMEN D et al.: Risperidone monotherapy in acute bipolar mania. 41st Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 8 - 12 (2002).
55. MEEHAN K, ZHANG F, DAVID S et al.: A double-blind, randomised comparison of the effecacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. (2001) 21:389-397.
56. LINDENMAYER JP, CZOBOR P, VOLAKAKA J et al.: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry (2003) 160:290-296.
57. NEWCOMER JW, HAUPT DW, FUCETOLA R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry (2002) 59:337-345.